Could adding these diabetes drugs early save lives? a new study investigates
NCT ID NCT07566299
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study uses health records from over 118,000 adults to compare early treatment strategies for people with obesity, type 2 diabetes, and related heart, kidney, and liver conditions. It looks at whether adding a GLP-1 or SGLT2 drug early, along with standard care, can reduce the risk of death over 5 years. The goal is to find the best way to manage these complex health problems together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chung Shan Medical University Hospital
Taichung, Taichung, 402, Taiwan
Conditions
Explore the condition pages connected to this study.